Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Cash & Equivalents (2016 - 2025)

Rein Therapeutics filings provide 10 years of Cash & Equivalents readings, the most recent being $3.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 75.01% year-over-year to $3.2 million, compared with a TTM value of $3.2 million through Dec 2025, down 75.01%, and an annual FY2025 reading of $3.2 million, down 75.01% over the prior year.
  • Cash & Equivalents hit $3.2 million in Q4 2025 for Rein Therapeutics, down from $4.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $21.9 million in Q2 2024, with the low at $3.2 million in Q4 2025.
  • Median Cash & Equivalents over the past 5 years was $7.7 million (2022), compared with a mean of $10.1 million.
  • The sharpest move saw Cash & Equivalents soared 233.81% in 2023, then plummeted 77.07% in 2025.
  • Year by year, Cash & Equivalents stood at $3.6 million in 2021, then surged by 44.28% to $5.2 million in 2022, then surged by 233.81% to $17.3 million in 2023, then decreased by 25.8% to $12.9 million in 2024, then plummeted by 75.01% to $3.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $3.2 million, $4.0 million, and $5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.